10x Genomics Secures Court Injunction Against Bruker's Sale of GeoMx Products in US

MT Newswires Live2024-12-24

10x Genomics (TXG) said late Monday a US court issued a permanent injunction against the sale of GeoMx products by Bruker (BRKR).

The US District Court for the District of Delaware will enter the injunction in January, which will prohibit Bruker from making, using, selling, or offering to sell the GeoMx Digital Spatial Profiler and associated instruments, reagents, and services for RNA and protein detection in the US.

These products were acquired from NanoString Technologies, according to 10x Genomics.

To ensure the continuity of the ongoing research, 10x said it requested an exemption for GeoMx users who installed an instrument before the trial in November 2023.

Additionally, 10x said that the court upheld the November 2023 jury verdict, which awarded the company $31 million in damages after finding that NanoString's GeoMx Digital Spatial Profiler products infringed patents licensed to 10x.

Neither Bruker nor NanoString immediately responded to MT Newswires' request for comment.

Shares of 10x Genomics were up nearly 2% in after-hours trading. Bruker shares were unchanged.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment